HEGP, Assistance-publique Hpitaux de Paris, INSERM U970, Universit Paris Descartes, France.
Drugs. 2011 Sep 10;71(13):1689-701. doi: 10.2165/11593790-000000000-00000.
Arterial stiffness has emerged as an important marker of cardiovascular risk in various populations and reflects the cumulative effect of cardiovascular risk factors on large arteries, which in turn is modulated by genetic background. Arterial stiffness is determined by the composition of the arterial wall and the arrangement of these components, and can be studied in humans non-invasively. Age and distending pressure are two major factors influencing large artery stiffness. Change in arterial stiffness with drugs is an important endpoint in clinical trials, although evidence for arterial stiffness as a therapeutic target still needs to be confirmed. Drugs that independently affect arterial stiffness include antihypertensive drugs, mostly blockers of the renin-angiotensin-aldosterone system, hormone replacement therapy and some antidiabetic drugs such as glitazones. While the quest continues for 'de-stiffening drugs', so far only advanced glycation endproduct cross-link breakers have shown promise.
动脉僵硬度已成为各种人群心血管风险的重要标志物，反映了心血管危险因素对大动脉的累积影响，而这反过来又受到遗传背景的调节。动脉僵硬度由动脉壁的组成和这些成分的排列决定，可以在人体上进行非侵入性研究。年龄和扩张压是影响大动脉僵硬度的两个主要因素。药物对动脉僵硬度的影响变化是临床试验中的一个重要终点，尽管动脉僵硬度作为治疗靶点的证据仍需确认。独立影响动脉僵硬度的药物包括降压药，主要是肾素-血管紧张素-醛固酮系统阻滞剂、激素替代疗法和一些如噻唑烷二酮类的降糖药物。虽然人们一直在寻找“软化药物”，但到目前为止，只有晚期糖基化终产物交联断裂剂显示出了希望。
